Ozempic and GLP-1 drugs: the risk of sudden vision loss

Once promoted as “miracle” slimming injections, some diabetes medicines now used for weight loss are facing renewed scrutiny from eye specialists.

As injectable weight-loss medicines become increasingly popular, two significant studies have prompted unsettling questions about an uncommon but severe adverse effect: sudden and, in some cases, irreversible sight loss.

Ozempic’s shift from diabetes medicine to slimming trend

Ozempic, Wegovy and Rybelsus were not created as cosmetic weight-loss products. All are medicines based on semaglutide, initially authorised to help people with type 2 diabetes manage their blood glucose levels.

These medicines replicate the action of a gut hormone known as GLP-1. It prompts the pancreas to produce insulin, delays digestion and delivers strong fullness signals to the brain. As a result, patients commonly become full sooner and remain satisfied for longer.

For many people, the effects include substantial weight reduction alongside improved blood pressure, cholesterol and blood glucose control. Among people living with obesity or diabetes, this may mean fewer heart attacks and strokes, as well as a longer and healthier life.

Social media transformed that clinical narrative into a different phenomenon. Images labelled “Ozempic face” and “skinny jabs” soon spread across TikTok and Instagram. Demand rose sharply among people who were not always at high risk or significantly overweight.

Behind the hype, researchers began to notice a faint but worrying pattern in the eye clinic waiting rooms.

What the new eye studies are actually saying

A rare condition with a scary nickname

The principal concern involves a complex condition called non-arteritic anterior ischemic optic neuropathy, or NAION. Ophthalmologists sometimes refer to it as a “stroke of the eye”.

NAION occurs when the blood supply to the optic nerve - the connection carrying visual signals from the eye to the brain - drops abruptly. The nerve fibres are deprived of oxygen and may die rapidly.

People generally wake with painless, sudden sight loss in one eye. They might experience a dark area, blurred patches or a shadow affecting part of their field of vision. In many instances, the resulting damage cannot be reversed.

NAION is uncommon, affecting only a few people in every 100,000 each year. Because it is so rare, even a modest signal can become noticeable during medicine safety monitoring.

The Massachusetts study: risk appears higher on semaglutide

One of the most widely discussed studies was conducted at Massachusetts Eye and Ear Hospital. Scientists tracked more than 16,000 patients with diabetes or obesity between 2017 and 2023.

They compared patients using semaglutide with those receiving other therapies, then recorded the number of people who developed NAION during the study.

The team found that NAION appeared more often in those using semaglutide: roughly four times higher risk in people with diabetes, and more than seven times higher in people with obesity.

This finding does not establish that semaglutide itself directly causes NAION. Patients prescribed semaglutide may differ from other patients in numerous respects, including disease severity and lifestyle. Nevertheless, the study’s scale and the apparent strength of the association concerned both specialists and regulators.

Swedish and Australian data point in the same direction

In separate research, teams from Sweden’s Karolinska Institutet and the University of Melbourne examined a large patient group taking GLP-1 medicines, including semaglutide.

They reported that NAION was still extremely uncommon, affecting roughly 0.04% of treated patients. However, the risk appeared slightly greater than among comparable people who were not taking these medicines.

Diabetes itself complicates the picture because it increases the likelihood of NAION. A 2013 meta-analysis published in PLOS ONE found that people with diabetes had a 64% greater risk of NAION, even in the absence of weight-loss injections.

This makes it challenging to separate the risk arising from the underlying condition from any risk potentially associated with the medicine. Rapid changes in blood glucose caused by treatment may contribute in susceptible people, although the exact mechanism remains unclear.

Regulators react while doctors weigh trade-offs

European regulators have already taken action. In June 2025, the European Medicines Agency included NAION on semaglutide’s official list of “very rare” side effects and advised patients to stop treatment at once if they experience sudden changes in vision.

Safety sheets now stress: any abrupt loss of vision, even in one eye and without pain, is an emergency that should halt injections until checked.

This presents doctors and patients with a familiar clinical balancing act. Semaglutide may reduce cardiovascular risk, improve diabetes management and support considerable, often life-changing weight loss. Against these benefits is a very rare but potentially serious threat to vision.

Who might be more vulnerable?

Eye specialists identify several factors that may increase the likelihood of NAION:

• Obstructive sleep apnoea
• High blood pressure
• Diabetes with long-standing vascular damage
• Previous visual problems or prior NAION in the other eye
• Unfavourable optic nerve anatomy, sometimes called a “crowded” optic disc
• Smoking and high cholesterol

People with these characteristics may already have impaired microcirculation - the network of minute blood vessels supplying the nerves and retina. Specialists are concerned that a medicine affecting blood flow, blood pressure or fluid balance could push an already vulnerable system beyond its limit.

What patients on Ozempic and similar drugs should watch for

For most patients, abandoning a very effective treatment because of a highly uncommon side effect is not necessarily appropriate. Instead, specialists are advocating more focused monitoring.

Doctors now encourage patients on GLP-1 drugs to treat their eyes the way they treat their hearts: as organs needing monitoring when major metabolic changes are underway.

Clinicians often suggest practical measures including:

• Arranging a baseline eye examination, including an assessment of the optic nerve, before beginning or shortly after beginning a GLP-1 medicine.
• Informing an ophthalmologist or optometrist that you take semaglutide or a similar medicine.
• Obtaining urgent assessment if you wake with new blind spots, sudden blurring or a dark curtain covering part of your vision.
• Maintaining regular checks of blood pressure, cholesterol and sleep apnoea.

Long-term research is also in progress. One ongoing study is following around 1,500 patients for five years, with the aim of establishing precisely how semaglutide affects retinal and optic nerve structure, and whether particular patterns can predict later problems.

Understanding the science behind GLP-1 drugs and eyesight

How GLP-1 treatments might influence the eye

Researchers are still exploring possible reasons for the association between GLP-1 agonists and NAION. Several explanations are under discussion:

None of these explanations has been definitively demonstrated. The eye is particularly sensitive to minor changes in circulation, while the combination of diabetes, obesity, sleep apnoea and potent metabolic medicines creates a complicated clinical picture.

Real-life scenarios: when caution becomes critical

Consider a middle-aged man with type 2 diabetes, high blood pressure and loud snoring that suggests sleep apnoea. His doctor prescribes Ozempic, and within several months his weight and blood glucose improve. One morning, he notices a blurred patch in his left eye when he wakes, but he has no pain. Believing it is caused by tiredness, he delays seeking help. By the time he visits an eye doctor, the damage is permanent and his sight cannot be recovered.

Now consider that same man after receiving advance warning about possible eye risks. He undergoes a baseline eye examination, receives treatment for sleep apnoea and understands that any sudden visual change requires urgent action. When a shadow first appears in his vision, he stops the injections and obtains an emergency assessment. The result may still be uncertain, but the opportunity for earlier intervention is much greater.

Balancing benefits, risks and long-term strategies

For people with severe obesity or poorly controlled diabetes, semaglutide and related GLP-1 medicines can be life-changing. Reducing pressure on the heart and blood vessels will generally also support eye health, as diabetic eye disease is closely connected to overall vascular health.

The central issue is not merely whether these medicines should be used, but how they can be prescribed sensibly. This involves recognising people with a vulnerable optic nerve, reducing the speed of weight loss where appropriate, and coordinating care between endocrinologists, GPs and eye specialists.

Patients thinking about GLP-1 treatment may wish to ask questions such as: “Do I have any known eye conditions?”, “Should I see an ophthalmologist before starting?” and “What warning signs mean I should stop the injections and call you?”. Straightforward answers to these practical questions are more important than viral before-and-after images.

Ultimately, rapid weight loss has physiological effects. Some, such as lower blood pressure, are beneficial. Others, including a small rise in the risk of sudden sight loss, demand frank discussion, careful monitoring and informed decisions by both doctor and patient.